INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Presence of chronic HCV infection based on chart   │ Presence of chronic HCV infection based on chart   │     100 │
│ review will be defined as positive for anti-HCV    │ review will be defined as positive for anti-HCV    │         │
│ antibody or HCV RNA at least 6 months before       │ antibody or HCV RNA at least 6 months before       │         │
│ screening                                          │ screening                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Liver biopsy at any time showing mHAI stage 4 or   │ Liver biopsy at any time showing mHAI stage 4 or   │     100 │
│ higher fibrosis OR                                 │ higher fibrosis OR                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ NOTE: If APRI and FIB-4 are discordant one of the  │ NOTE: If APRI and FIB-4 are discordant one of the  │     100 │
│ other forms of fibrosis staging must be used       │ other forms of fibrosis staging must be used       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hemochromatosis                                    │ Hemochromatosis                                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Alpha-1 antitrypsin deficiency                     │ Alpha-1 antitrypsin deficiency                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Wilson's disease                                   │ Wilson's disease                                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Autoimmune hepatitis                               │ Autoimmune hepatitis                               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Alcoholic liver disease                            │ Alcoholic liver disease                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Drug-related liver disease                         │ Drug-related liver disease                         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe NC confounding conditions (stroke, head     │ Severe NC confounding conditions (stroke, head     │     100 │
│ injury, or developmental learning disability)      │ injury, or developmental learning disability)      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Regular use of anti-inflammatory drugs             │ Regular use of anti-inflammatory drugs             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current or recent treatment with pegylated         │ Current or recent treatment with pegylated         │     100 │
│ interferon (PEG-IFN)                               │ interferon (PEG-IFN)                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other active inflammatory process (major           │ Other active inflammatory process (major           │     100 │
│ infection, malignancy, rheumatoid                  │ infection, malignancy, rheumatoid                  │         │
│ arthritis/autoimmune disorder) within the prior 28 │ arthritis/autoimmune disorder) within the prior 28 │         │
│ days                                               │ days                                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Uncontrolled or active depression or other         │ Uncontrolled or active depression or other         │     100 │
│ psychiatric disorder that in the opinion of the    │ psychiatric disorder that in the opinion of the    │         │
│ site investigator might preclude adherence to      │ site investigator might preclude adherence to      │         │
│ study requirements or impact NC functioning and    │ study requirements or impact NC functioning and    │         │
│ assessments                                        │ assessments                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active drug or alcohol use or dependence that, in  │ Active drug or alcohol use or dependence that, in  │     100 │
│ the opinion of the site investigator, would        │ the opinion of the site investigator, would        │         │
│ interfere with adherence to study requirements     │ interfere with adherence to study requirements     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of active or acute AIDS-defining          │ Presence of active or acute AIDS-defining          │     100 │
│ opportunistic infections within 12 weeks prior to  │ opportunistic infections within 12 weeks prior to  │         │
│ study entry                                        │ study entry                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Adults (18 years old or older) with chronic HCV    │ Adult (= 18 years old) subjects with chronic       │      85 │
│ and NCI with a GDS greater than or equal to 0.35   │ genotype 1 HCV and NCI with a GDS greater than or  │         │
│ (n=40)                                             │ equal to 0.5 (n=60)                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ FibroScan within 12 months demonstrating liver     │ FibroScan within 12 months demonstrating liver     │      91 │
│ stiffness of ≥9.5 kPa OR                           │ stiffness of =9.5 kilo Pascal or                   │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years                  │ Liver biopsy at any time showing mHAI stage 4 or   │      38 │
│                                                    │ higher fibrosis OR                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Plan to receive HCV treatment from their primary   │ Current or recent treatment with pegylated         │      45 │
│ care physician within 1 month of enrollment        │ interferon (PEG-IFN)                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any cause of liver disease other than chronic HCV  │ Presence of active or acute AIDS-defining          │      46 │
│ infection, including but not limited to the        │ opportunistic infections within 12 weeks prior to  │         │
│ following                                          │ study entry                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Cirrhosis or bridging fibrosis (mHAI stages 4-6 or │ Liver biopsy at any time showing mHAI stage 4 or   │      47 │
│ its equivalent)                                    │ higher fibrosis OR                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ APRI ≥2.0 and FIB-4 ≥3.25                          │ AST to platelet ratio index (APRI) =2.0 and        │      49 │
│                                                    │ Fibrosis-4 (FIB-4) =3.25                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ For the HIV/HCV co-infected group only, subjects   │ For the HIV/HCV co-infected group only, subjects   │      83 │
│ must have HIV. HIV status will be obtained through │ must have HIV. HIV status will be obtained through │         │
│ self-report. Self-report will be confirmed at the  │ self report. Self report will be confirmed at      │         │
│ pretreatment visit using a HIV-1 point of care     │ screening using a HIV-1 point of care test. In the │         │
│ test. In the event that point of care test and     │ event that point of care test and self-report are  │         │
│ self-report are discordant, then HIV status will   │ discordant, then HIV status will be confirmed by a │         │
│ be confirmed by a licensed Western blot or a       │ licensed Western blot or a second antibody test    │         │
│ second antibody test by a method other than the    │                                                    │         │
│ initial rapid HIV-1 and/or E/CIA, or by HIV-1      │                                                    │         │
│ antigen, or plasma HIV-1 RNA viral load            │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Drug-related liver disease                         │ Platelets >150,000                                 │      32 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Cirrhosis or bridging fibrosis (mHAI stages 4-6 or │ Creatinine clearance >30 milliliters/minute/1.73   │      35 │
│ its equivalent)                                    │ centimeter squared                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Plan to receive HCV treatment from their primary   │ Aspartate aminotransferase (AST)/Alanine           │      36 │
│ care physician within 1 month of enrollment        │ aminotransferase (ALT) <10x upper limit of normal  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Plan to receive HCV treatment from their primary   │ P-glycoprotein (P-gp) inducers (e.g., rifampin,    │      36 │
│ care physician within 1 month of enrollment        │ St. John's wort)                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Wilson's disease                                   │ Amiodarone                                         │      38 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of chronic HCV infection based on chart   │ HIV/HCV co-infected subjects (n=12) must also have │      39 │
│ review will be defined as positive for anti-HCV    │ a HIV RNA measurement <50 copies/mL at the pre-    │         │
│ antibody or HCV RNA at least 6 months before       │ treatment visit                                    │         │
│ screening                                          │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active drug or alcohol use or dependence that, in  │ Bleeding diathesis, thrombocytopenia, or use of    │      41 │
│ the opinion of the site investigator, would        │ anticoagulants that would contraindicate lumbar    │         │
│ interfere with adherence to study requirements     │ puncture                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe NC confounding conditions (stroke, head     │ Contraindications to magnetic resonance imaging    │      43 │
│ injury, or developmental learning disability)      │ (MRI)                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any cause of liver disease other than chronic HCV  │ Known allergy/sensitivity or any hypersensitivity  │      44 │
│ infection, including but not limited to the        │ to components of study drugs or their formulation  │         │
│ following                                          │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ APRI ≥2.0 and FIB-4 ≥3.25                          │ AST to platelet ratio index (APRI) =2.0 and        │      49 │
│                                                    │ Fibrosis-4 (FIB-4) =3.25                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ For the HIV/HCV co-infected group only, subjects   │ For the HIV/HCV co-infected group only, subjects   │      83 │
│ must have HIV. HIV status will be obtained through │ must have HIV. HIV status will be obtained through │         │
│ self-report. Self-report will be confirmed at the  │ self report. Self report will be confirmed at      │         │
│ pretreatment visit using a HIV-1 point of care     │ screening using a HIV-1 point of care test. In the │         │
│ test. In the event that point of care test and     │ event that point of care test and self-report are  │         │
│ self-report are discordant, then HIV status will   │ discordant, then HIV status will be confirmed by a │         │
│ be confirmed by a licensed Western blot or a       │ licensed Western blot or a second antibody test    │         │
│ second antibody test by a method other than the    │                                                    │         │
│ initial rapid HIV-1 and/or E/CIA, or by HIV-1      │                                                    │         │
│ antigen, or plasma HIV-1 RNA viral load            │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 81
Average Levenshtein Ratio of individual lines: 73.14285714285714
OverAll Ratio: 77.07142857142857
